Last reviewed 2026-04-22 · How we verify

SFC

SFC is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing.

SFC is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.

At a glance

Mechanism of action

The fluticasone propionate component suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, while salmeterol is a long-acting beta-2 agonist that stimulates bronchial smooth muscle relaxation. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained symptom control in obstructive airway diseases.

Approved indications

• Asthma maintenance treatment
• Chronic obstructive pulmonary disease (COPD) maintenance treatment

Common side effects

• Tremor
• Headache
• Palpitations
• Oral candidiasis
• Muscle cramps

Key clinical trials

• Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients (PHASE3)
• A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors (PHASE1)
• First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study (PHASE1)
• Solution-focused Counseling for Menopausal Symptoms (NA)
• Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery (PHASE2)
• A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine (PHASE1)
• A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines. (PHASE1)
• ALACOVID Study for Vaccinated Subjects (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.